Oral Hereditary Angioedema Shift And Global Expansion Will Reshape This Undervalued Opportunity

Catalysts

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a biopharmaceutical company focused on oral therapies for hereditary angioedema, including its on demand treatment EKTERLY.

What are the underlying business or industry changes driving this perspective?

• Early EKTERLY uptake in high burden hereditary angioedema patients, reflected in 937 U.S. start forms within roughly 4 months and refill patterns more frequent than historical injectable on demand therapies, points to a treatment shift that could support higher on demand prescription volumes and revenue per patient.
• Growing real world experience in KONFIDENT-S, with over 2,700 attacks treated and declining use of second doses and injectable rescue therapy by attack 30, suggests increasing confidence in a single oral agent. This can support adherence and potentially improve gross to net stability as payer comfort grows.
• International rollout, including launches in the U.S. and Germany and approvals in the U.K., EU, Switzerland and Australia, together with planned launches in the U.K. and Japan in 2026, broadens the addressable market. This can influence total revenue and help spread fixed operating costs over a larger sales base.
• Payer behavior, with medical exceptions already approved by all major pharmacy benefit managers and large commercial and Medicare payers and an objective to formalize broad access in early 2026, creates a pathway for a higher mix of paid prescriptions that can support revenue visibility and net margins over time.
• Expansion into pediatric hereditary angioedema through the KONFIDENT-KID trial, which is fully enrolled and expected to support a pediatric NDA submission in Q3 2026, offers potential for EKTERLY to cover a wider age range and treat more frequent attacks in children. This can affect long term revenue growth and earnings leverage.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming KalVista Pharmaceuticals's revenue will grow by 492.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from -14242.4% today to 3.6% in 3 years time.
• Analysts expect earnings to reach $10.7 million (and earnings per share of $0.43) by about January 2029, up from $-203.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $161.4 million in earnings, and the most bearish expecting $-34.5 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 190.0x on those 2029 earnings, up from -3.9x today. This future PE is greater than the current PE for the US Biotechs industry at 21.1x.
• Analysts expect the number of shares outstanding to grow by 1.62% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.35%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• If high burden hereditary angioedema patients are driving a large share of current EKTERLY prescriptions and refills, a future shift toward lower burden patients with fewer attacks could mean fewer refills per year and smaller shipment quantities, which would put pressure on revenue growth and limit operating leverage.
• Guidance that refill patterns and utilization may "normalize" as EKTERLY adoption moves beyond the highest burden segment suggests that the current level of demand might not be representative of the long term average. As a result, a reset in ordering and stocking behavior by both patients and specialty pharmacies could weigh on revenue and slow improvement in earnings.
• Payers are still moving from medical exception access to formal policies for EKTERLY and some already impose quantity limits or step through requirements. If longer term reimbursement terms are tighter than the early access period, this could cap paid prescription volumes, affect gross to net outcomes and delay any path to positive net margins.
• KalVista is investing heavily in commercialization, with quarterly SG&A expenses of US$46.5 million against EKTERLY sales of US$13.7 million. If international launches, pediatric expansion and broader adoption do not scale quickly enough to absorb these fixed costs, the company could continue to report losses and weaker earnings than analysts currently expect.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $31.0 for KalVista Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $39.0, and the most bearish reporting a price target of just $22.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $297.2 million, earnings will come to $10.7 million, and it would be trading on a PE ratio of 190.0x, assuming you use a discount rate of 7.3%.
  
• Given the current share price of $15.66, the analyst price target of $31.0 is 49.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.